BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer

Breast Journal

Volumn 9, Issue 3, 2003, Pages 167-174

  Kim, Sung ^a   Rimm, David ^a   Carter, Darryl ^a   Khan, Atif ^a   Parisot, Nicole ^a   Franco, Mayra Alvarez ^a   Bale, Allen ^a   Haffty, Bruce G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Molecular markers

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLINE; ESTROGEN RECEPTOR; MOLECULAR MARKER; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; EARLY CANCER; EVALUATION; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; ONCOGENE; ONCOGENE NEU; PREMENOPAUSE; SYSTEMIC THERAPY; TREATMENT INDICATION; WILD TYPE;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASM RECURRENCE, LOCAL; PREMENOPAUSE; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037736549     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2003.09307.x     Document Type: Article

References (15)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Cancer risks in BRCA 2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-16.
3. Bertwistle D, Ashworth A. BRCA1 and BRCA2. Curr Biol 2000;10:R582.
4. Bishop DT. BRCA1 and BRCA2 and breast cancer incidence: a review. Ann Oncol 1999;10(suppl 6):113-19.
5. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-28.
6. Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 1996;5 Spec No:1515-19.
7. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80:435-41.
8. Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-71.
9. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:310-19.
10. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2- associated hereditary breast carcinoma in Japanese women. Cancer 1999;85:2200-205.
11. Gretarsdottir S, Thorlacius S, Valgardsdottir R, et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998;58:859-62.
12. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-17.
13. Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002;359:1471-77.
14. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000;39:327-33.
15. Silvestrini R, Daidone MG, Benini E, et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 1996;2:2007-13.